DDInter1340 DDInter1251
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is marketed by Roche Pharmaceuticals and was granted FDA approval for the prophylaxis of transplant rejection in 1995. In addition to the above uses, mycophenolate mofetil has also been studied for the treatment of nephritis and other complications of autoimmune diseases. Unlike another immunosuppressant class, the calcineurin inhibitors, MMF generally does not cause nephrotoxicity or fibrosis.[A180799,A180805] Previously, mycophenolic acid (MPA) was administered to individuals with autoimmune diseases beginning in the 1970s, but was discontinued due to gastrointestinal effects and concerns over carcinogenicity. The new semi-synthetic 2-morpholinoethyl ester of MPA was synthesized to avoid the gastrointestinal effects associated with the administration of MPA. It demonstrates an increased bioavailability, a higher efficacy, and reduced gastrointestinal effects when compared to MPA.
Omeprazole {u} (Compound) palliates {v} (Disease) systemic scleroderma
systemic scleroderma {u} (Disease) is treated by {v} (Compound) Mycophenolate mofetil
Omeprazole {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Mycophenolate mofetil
Omeprazole {u} (Compound) causes {v} (Side Effect) Creatinine increased
Creatinine increased {u} (Side Effect) is caused by {v} (Compound) Mycophenolate mofetil
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Omeprazole {u} (Compound) palliates {v} (Disease) systemic scleroderma
systemic scleroderma {u} (Disease) is treated by {v} (Compound) Mycophenolic acid
Mycophenolic acid {u} (Compound) resembles {v} (Compound) Mycophenolate mofetil
Omeprazole {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) regulates {v} (Gene) FAM63A
FAM63A {u} (Gene) is upregulated by {v} (Compound) Mycophenolate mofetil
Omeprazole {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) interacts with {v} (Gene) DNAJB1
DNAJB1 {u} (Gene) is downregulated by {v} (Compound) Mycophenolate mofetil
Omeprazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is downregulated by {v} (Disease) systemic scleroderma
systemic scleroderma {u} (Disease) is treated by {v} (Compound) Mycophenolate mofetil
Omeprazole (Compound) palliates systemic scleroderma (Disease) and systemic scleroderma (Disease) is treated by Mycophenolate mofetil (Compound)
Omeprazole (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Mycophenolate mofetil (Compound)
Omeprazole (Compound) causes Creatinine increased (Side Effect) and Creatinine increased (Side Effect) is caused by Mycophenolate mofetil (Compound)
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil
Omeprazole (Compound) palliates systemic scleroderma (Disease) and systemic scleroderma (Disease) is treated by Mycophenolic acid (Compound) and Mycophenolic acid (Compound) resembles Mycophenolate mofetil (Compound)
Omeprazole (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) regulates FAM63A (Gene) and FAM63A (Gene) is upregulated by Mycophenolate mofetil (Compound)
Omeprazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) interacts with DNAJB1 (Gene) and DNAJB1 (Gene) is downregulated by Mycophenolate mofetil (Compound)
Omeprazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is downregulated by systemic scleroderma (Disease) and systemic scleroderma (Disease) is treated by Mycophenolate mofetil (Compound)